VELVET (Veltuzumab Various Doses Exploratory Trial), a Randomized, Double Blind, Placebo Controlled, Multicentre, Multinational Phase II Dose Range Finding Trial in Subjects With Moderate to Severe Rheumatoid Arthritis Insufficiently Controlled With Either Methotrexate Alone or Methotrexate Plus Anti-tumour Necrosis Factor Biological Treatment, Comparing 3 Different Subcutaneous Dosages of Anti-CD20 Monoclonal Antibody Veltuzumab to Placebo as an add-on Therapy to Methotrexate.

This is a multi-national, multi-centre, placebo-controlled, double-blind, randomized, 4-arm parallel group trial, comparing three different dose levels (80 mg, 160 mg and 320 mg) of veltuzumab to placebo, administered weekly (days 1, 8, 15 and 22) by subcutaneous (sc) injection to subjects with moderate to severe rheumatoid arthritis (RA) (cumulative veltuzumab doses 320 mg, 640 mg, and 1280 mg, respectively). All subjects will be on continued stable co-medication with methotrexate (MTX).

开始日期2011-08-01

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

EUCTR2010-022378-15-ES / Not yet recruitingN/A

VELVET (Veltuzumab various doses exploratory trial), a randomized, double blind, placebo controlled, multicentre, multinational phase II dose range finding trial in subjects with moderate to severe rheumatoid arthritis insufficiently controlled with either methotrexate alone or methotrexate plus anti-tumour necrosis factor biological treatment, comparing 3 different subcutaneous dosages of anti-CD20 monoclonal antibody veltuzumab to placebo as an add-on therapy to methotrexate. - VELVET

开始日期2011-05-19

申办/合作机构

Nycomed GmbH

100 项与维妥珠单抗相关的临床结果

登录后查看更多信息

100 项与维妥珠单抗相关的转化医学

登录后查看更多信息

100 项与维妥珠单抗相关的专利（医药）

登录后查看更多信息

1,860

项与维妥珠单抗相关的文献（医药）

2024-10-01·AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Rituximab as a Therapeutic Strategy in Hemophagocytic Lymphohistiocytosis: Efficacy, Outcomes, and Survival—Insights From a Systematic Review

Review

作者: Altaf, Faryal ; Jamil, Abdur ; Siddique, Rimsha ; Qureshi, Zaheer

Background::

Hemophagocytic lymphohistiocytosis (HLH) is a severe immunologic disorder that can be fatal if left untreated. The condition is characterized by excessive immune system activation and is often triggered by infections such as Epstein-Barr virus (EBV). Rituximab, an anti-CD20 monoclonal antibody, has been suggested as a treatment, particularly for EBV-associated HLH.

Methods::

A systematic review was conducted using PRISMA guidelines, with a literature search spanning PubMed, Scopus, Web of Science, and the Cochrane Library. The inclusion criteria focused on studies that assessed rituximab’s efficacy in treating HLH. Quality assessment was performed using the Joanna Briggs Institute Critical Appraisal Checklist for Case Reports.

Results::

Of 783 identified records, 24 studies were included in the final analysis. Rituximab was typically administered at 375 mg/m2, with varying doses and treatment frequency. Clinical response, often seen within 1 month, was assessed by improvements in clinical symptoms and laboratory findings. Survival rates posttreatment displayed a wide range, with instances of complete remission and disease-free periods, as well as reports of relapse and mortality.

Conclusions::

Rituximab demonstrates the potential for significant clinical benefit in treating HLH, particularly when associated with EBV, showing promise in reducing disease activity and contributing to remission. These findings encourage further research and clinical trials to refine the therapeutic protocols and better understand the long-term effects of rituximab in HLH management.

2024-09-25·Science Translational Medicine

B cells drive neuropathic pain–related behaviors in mice through IgG–Fc gamma receptor signaling

Article

作者: Farinotti, Alex Bersellini ; Funk, Geoffrey A. ; Bavencoffe, Alexis ; Shiers, Stephanie ; Heijnen, Cobi J. ; Willcox, Kendal F. ; Zuberi, Younus A. ; Grace, Peter M. ; Fiore, Nathan T. ; Boukelmoune, Nabila ; Sankaranarayanan, Ishwarya ; Tavares-Ferreira, Diana ; Hutchinson, Mark R. ; Lacagnina, Michael J. ; Dayani, Dorsa ; Chavez, Melissa V. ; Svensson, Camilla I. ; Price, Theodore J. ; Barratt, Daniel T. ; Barry, Allison M. ; Mwirigi, Juliet M. ; Lu, Jonathan T. ; Cervantes, Anna M. ; Walters, Edgar T.

Neuroimmune interactions are essential for the development of neuropathic pain, yet the contributions of distinct immune cell populations have not been fully unraveled. Here, we demonstrate the critical role of B cells in promoting mechanical hypersensitivity (allodynia) after peripheral nerve injury in male and female mice. Depletion of B cells with a single injection of anti-CD20 monoclonal antibody at the time of injury prevented the development of allodynia. B cell–deficient (muMT) mice were similarly spared from allodynia. Nerve injury was associated with increased immunoglobulin G (IgG) accumulation in ipsilateral lumbar dorsal root ganglia (DRGs) and dorsal spinal cords. IgG was colocalized with sensory neurons and macrophages in DRGs and microglia in spinal cords. IgG also accumulated in DRG samples from human donors with chronic pain, colocalizing with a marker for macrophages and satellite glia. RNA sequencing revealed a B cell population in naive mouse and human DRGs. A B cell transcriptional signature was enriched in DRGs from human donors with neuropathic pain. Passive transfer of IgG from injured mice induced allodynia in injured muMT recipient mice. The pronociceptive effects of IgG are likely mediated through immune complexes interacting with Fc gamma receptors (FcγRs) expressed by sensory neurons, microglia, and macrophages, given that both mechanical allodynia and hyperexcitability of dissociated DRG neurons were abolished in nerve-injured FcγR-deficient mice. Consistently, the pronociceptive effects of IgG passive transfer were lost in FcγR-deficient mice. These data reveal that a B cell–IgG–FcγR axis is required for the development of neuropathic pain in mice.

2024-09-18·CLINICAL NEPHROLOGY

Treating primary membranous nephropathy with extremely high titer of anti-phospholipase A2 receptor antibodies: A case of failed treatment with very high-dose rituximab

Article

作者: Sun, Jingshu ; Wang, Jianying ; Wu, Shengqin ; Yin, Fang ; Zhang, Kunying

Rituximab (RTX) is the anti-CD20 monoclonal antibody that has been used as the first-line therapy for primary membranous nephropathy (PMN) in recent years. However, the optimal dosing regimen and timing of RTX, or combination with other immunosuppressants, especially in patients with extremely high titers (> 1,000 RU/mL) of anti-PLA2R antibody (aPLA2R), are unclear at present. This report describes the case of a 70-year-old PMN patient with extremely high aPLA2R titer who failed to respond to very high doses of RTX. We also discuss the possible reasons for treatment failure.

项与维妥珠单抗相关的新闻（医药）

2024-09-18

·novartis

New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients

Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1 More than 80% of patients receiving first-line Kesimpta were progression-free for up to six years, reinforcing the value of introducing Kesimpta early1 Patients switching to Kesimpta from IV anti-CD20 therapy showed no new active lesions (Gd+ T1) 12 months after switch in separate US single-arm, open-label, Phase IIIb OLIKOS study2 Basel, September 18, 2024 – Novartis today announced new data from the ALITHIOS open-label extension study. Data show first-line Kesimpta® (ofatumumab) treatment for up to six years led to less disability and disease progression in recently diagnosed (≤3 years) and treatment-naïve (RDTN) people with relapsing multiple sclerosis (RMS), compared to those who switched from teriflunomide1. A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new gadolinium-enhancing (Gd+) T1 lesions, a commonly used marker of disease activity, compared to baseline2. These data will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting in Copenhagen, Denmark on September 18-20. “We continue to study the efficacy and safety of Kesimpta in different populations of people living with relapsing multiple sclerosis as part of our mission to advance care,” said Norman Putzki, M.D., Ph.D., Global Development Unit Head, Neuroscience & Gene Therapy, Novartis International AG. “Novartis is committed to understanding and solving some of the most burdensome neurological conditions to improve the quality of life for patients and their caregivers, and to make a positive impact on society.” Kesimpta benefits in first-line patients Data from the overall ALITHIOS study population showed that continuous use of Kesimpta was associated with numerically fewer 6-month confirmed disability worsening (6mCDW) and progression independent of relapse activity (6mPIRA) events up to six years compared to those who switched from teriflunomide1. These benefits appeared more pronounced in the RDTN subgroup, defined as starting treatment within three years of diagnosis1. RDTN patients receiving continuous Kesimpta were more likely to remain free from 6mCDW compared to those who switched to Kesimpta from teriflunomide (83.4% vs. 76.3%)1. RDTN patients receiving continuous Kesimpta were also more likely to be free of 6mPIRA vs. switching from teriflunomide (88.9% vs. 83.3%)1. “These data showed that people recently diagnosed with relapsing multiple sclerosis who received first-line Kesimpta had fewer disability worsening events and greater likelihood of being progression-free,” said lead investigator Amit Bar-Or, M.D., Director of the Center for Neuroinflammation and Neurotherapeutics at the University of Pennsylvania. “The reduction of disability accumulation observed early in the disease course supports earlier adoption of Kesimpta.” Limitations of the results include a potential for attrition bias and the open-label nature of the extension study1. No new T1 lesions in patients who switched from IV therapy to KesimptaThe US-based OLIKOS study analyzed 102 clinically stable RMS patients who switched from previous IV anti-CD20 therapy (99% from ocrelizumab) to Kesimpta2. For 84 patients with MRI results, no new Gd+ T1 lesions were observed at 12 months, the study’s primary endpoint. Additionally, 98% of patients did not develop new/enlarging T2 (NeT2) lesions at 12 months, an exploratory endpoint in the study2. Treatment-emergent adverse events (TEAEs) occurred at a similar frequency as in the core Phase III ASCLEPIOS clinical trials, with no new safety signals identified2. The most commonly reported (≥10%) TEAEs were COVID-19, headache, fatigue, and urinary tract infection. Mean serum immunoglobulin G (IgG) and IgM levels remained stable up to 12 months2. About Multiple SclerosisMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by myelin destruction and axonal damage in the brain, optic nerves and spinal cord3. MS, which affects nearly 3 million people worldwide4, can be characterized into four main types: clinically isolated syndrome (CIS), relapsing-remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS)5. The various forms of MS can be distinguished based on whether a patient experiences relapses (clearly defined acute inflammatory attacks of worsening neurological function), and/or whether they experience progression of neurologic damage and disability from the onset of the disease3. About Kesimpta® (ofatumumab)Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that provides the flexibility of self-administration for adults with relapsing forms of multiple sclerosis (RMS). It is an anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly injection, delivered subcutaneously6-9. Initial doses of Kesimpta are at Weeks 0, 1 and 2, with the first injection performed under the guidance of a healthcare professional6,7. The selective mechanism of action and subcutaneous administration of Kesimpta allows precise delivery to the lymph nodes, where B-cell depletion in MS is needed, and preclinical studies have shown that it may preserve the B-cells in the spleen10. Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline. Novartis obtained rights for ofatumumab from GlaxoSmithKline in all indications, including RMS, in December 201511. Kesimpta has been approved for the treatment of relapsing forms of multiple sclerosis in over 90 countries worldwide with more than 100,000 patients treated as of August 20246,7,12. Novartis in NeuroscienceAt Novartis, we have been tackling neurological conditions for more than 80 years, launching transformative treatments which have made meaningful differences to millions of people worldwide now and in the future. We continue to collaborate on industry-leading treatments in multiple sclerosis, pediatric neurology, neurodegeneration and neuroinflammation and psychiatry. DisclaimerThis media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise. About NovartisNovartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Bar-Or A, Hauser SL, Cohen JA, et al. Early Initiation of Ofatumumab Delays Disability Progression in People With Relapsing Multiple Sclerosis: 6-Year Results From ALITHIOS Open-Label Extension Study. Poster presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting; September 18–20, 2024; Copenhagen, Denmark. Hua LH, Brown B, Camacho E, et al. Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study. Poster presentation at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting; September 18–20, 2024; Copenhagen, Denmark. Guthrie E. Multiple sclerosis: A primer and update. Adv Studies Pharm. 2007;4(11):313-317. Portaccio E, Magyari M, Kubala Havrdova E, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg. Health Eur. 2024;44:100977. National Multiple Sclerosis Society. Types of MS. Available from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS Accessed September 10, 2024 Kesimpta. Prescribing Information. Novartis Pharmaceuticals Corporation East Hanover. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125326s079lbl… Accessed September 11, 2024. Kesimpta. Summary of Product Characteristics. Novartis Ireland Limited. 2023. https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information_en.pdf Accessed June 23, 2024. Hauser SL, Kappos L, Bar-Or A, et al. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Neurol Ther. 2023;12(5):1491-1515. Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study. Poster presentation at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Forum; February 27–29, 2020; West Palm Beach, FL, US. Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presentation at: the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting 2016; September 14–17, 2016; London, UK. Genmab. Press Release: Genmab announces completion of agreement to transfer remaining ofatumumab rights. December 21, 2015. Available from: https://ir.genmab.com/static-files/9d491b72-bb0b-4e46-a792-dee6c29aaf7d Accessed September 10, 2024. Novartis. Data on file. Novartis Media RelationsE-mail: media.relations@novartis.com Central North America Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414 Anna Schäfers +41 79 801 7267 Switzerland Satoshi Sugimoto +41 79 619 2035 Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com Central North America Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440 Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921 Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

临床结果临床3期上市批准

2024-08-27

·PRNewswire

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (r/r MCL). This is the third marketing approval on Carteyva® submitted by JW Therapeutics, and is the first cell therapy product approved in China for the treatment of patients with r/r MCL. Carteyva® was granted, by NMPA, Breakthrough Therapy Designation in Mar 2022, as well as Priority Review in Dec 2023. MCL is a heterogeneous B cell non-Hodgkin lymphoma which is currently incurable with existing therapies[1]. MCL, associated with a poor prognosis, mainly occurs in elderly men who were not diagnosed until advanced stage[2]. Significant progress has been made in the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted therapies such as bruton tyrosine kinase inhibitors (BTKi). Despite the use of BTKi in r/r MCL has improved their survival outcomes, many patients will ultimately relapse with shortened remission durations (6~10 months) [3]. Notwithstanding the above, there are still unmet medical needs for a safe, effective novel approach to overcome the limitations of current treatments of r/r MCL. The sBLA was supported by the clinical results from a single-arm, multi-center, pivotal study on Carteyva® in adult patients with r/r MCL in China. In the study, patients with r/r MCL who had been treated with a CD20-targeting antibody, anthracycline or bendamustine, or BTKis were included. After being treated with lymphodepleting chemotherapy, patients received Carteyva® (100×106 CAR+ T cells). As of August 7th, 2023, a total of 59 patients received Carteyva® infusion. Of 59 efficacy evaluable patients, Carteyva® demonstrated remarkable clinical responses achieving high rates of objective response rate (ORR) and complete response rate (CRR) (best ORR 81.36%, best CRR 67.80%) and the incidence of severe (grade ≥ 3) cytokine release syndrome (CRS) was 6.8%, the incidence of severe (grade ≥ 3) neurotoxicity (NT) was 6.8%. Sophia Yang, Senior Vice President and Head of Regulatory, Research & Development of JW Therapeutics, noted: "We are delighted to have a product that can deliver meaningful efficacy in this disease, nearly 70% of patients with r/r MCL have achieved complete remission after treatment with Carteyva®, and the overall safety data demonstrated that the treatment was generally well-tolerated. Carteyva® becomes the first commercial CAR-T cell product for the treatment of r/r MCL in China." References The consensus of the diagnosis and treatment of mantle cell lymphoma in China (2016 version). Chin J Hematol.2016, 37(9):735-741. Herrmann A, Hoster E, Zwingers T, et al. Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma[J]. Journal of Clinical Oncology, 2009, 27(4):511-518. Burkart M, Karmali R. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. J Pers Med. 2022 Mar 1;12(3):376. About Relmacabtagene Autoleucel Injection Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, Carteyva® has been approved by the China National Medical Products Administration (NMPA) for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBLC) after two or more lines of systemic therapy, the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), and the treatment of adult patients with relapsed or refractory mantle cell lymphoma ("r/r MCL") after two or more lines of systemic therapy including bruton tyrosine kinase inhibitors ("BTKi"), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations. About JW Therapeutics JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry. For more information, please visit . Forward-Looking Statements The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: . SOURCE JW Therapeutics

免疫疗法上市批准细胞疗法突破性疗法优先审批

2024-08-06

·PipelineReview

Indapta Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of IDP-023 for Progressive Multiple Sclerosis

Company’s g-NK Cell Therapy Has Multiple Potential Mechanisms That Could Impact Biology of Multiple Sclerosis HOUSTON, TX & SEATTLE, WA, USA I August 06, 2024 I Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today announced that the U.S. FDA has cleared the IND for the company’s Phase 1 clinical trial of its g-natural killer (g-NK) cell therapy, IDP-023, in progressive multiple sclerosis (MS). Stanford University and the University of California, San Francisco (UCSF) will lead the clinical trial. People with progressive MS will receive IDP-023 in combination with the anti-CD20 monoclonal antibody, ocrelizumab. The study will interrogate the biologic effects of IDP-023 using a translational program developed in collaboration with Stanford and UCSF. “I am excited to participate in this clinical trial because of the multiple potential mechanisms by which g-NK cells may impact the biology of MS,” said Dr. Lawrence Steinman, Professor of Medicine and Principal Investigator at Stanford. “In addition to being able to achieve B cell depletion by combining with a B cell directed monoclonal antibody, g-NK cells have the ability to kill HLA-E expressing autoreactive T and B cells. In addition, g-NK cells have potent anti-viral activity, and therefore may also address the Epstein Barr Virus reservoir that contributes to the disease pathogenesis.” Indapta is currently conducting a Phase 1/2 trial of IDP-023 in patients with non-Hodgkin’s lymphoma and multiple myeloma. “This IND is another in a series of milestone achievements from our team in recent months,” said Dr. Mark Frohlich, CEO of Indapta. “We look forward to the second half of the year during which we plan to initiate this trial and continue progress with our ongoing Phase 1/2 trial of IDP-023 in patients with hematologic cancers, where we have seen very encouraging responses to date.” Indapta’s Proprietary g-NK Cell Therapy Indapta’s universal, allogeneic NK cell therapy platform consists of a potent subset of naturally occurring NK cells, known as “g minus” NK cells, or “g-NK” cells. G‑NK cells arise from epigenetic changes resulting from exposure to cytomegalovirus (CMV). To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability. IDP-023 has several differentiated mechanisms of killing target cells without the need for genetic engineering, including highly robust antibody-dependent cell mediated cytotoxicity (ADCC), the targeting of HLA-E expressing cells via the NKG2C receptor, and the inherent anti-viral activity of g-NK cells. Indapta’s g-NK can release dramatically more immune activating cytokines and cell-killing compounds than conventional NK cells. In preclinical studies, IDP-023 has demonstrated more potent and durable antitumor activity when combined with cancer targeting monoclonal antibodies as compared to conventional NK cells. (Bigley et al., Blood Advances 2021, https://doi.org/10.1182/bloodadvances.2020002440 ). g-NK cells in combination with a B cell targeting antibody can also deplete normal B cells from healthy donors or patients with autoimmune disease. About Indapta Therapeutics Indapta is a privately held company focused on developing and bringing to market a diverse pipeline of cell therapies to treat the still unmet medical needs of patients with blood and solid-tumor cancers as well as autoimmune diseases. The company’s proprietary robust platform of naturally occurring g-NK cells is specifically designed to create best-in-class, highly potent, more accessible, and scalable cell therapies. For more information, please visit www.indapta.com . SOURCE: Indapta Therapeutics

细胞疗法临床申请免疫疗法临床1期

100 项与维妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09031	维妥珠单抗	-	DB05656

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	美国	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	阿根廷	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	加拿大	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	捷克	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	德国	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	匈牙利	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	意大利	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	墨西哥	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	波兰	Takeda Pharmaceutical Co., Ltd.	2011-08-01
肿瘤	临床2期	西班牙	Takeda Pharmaceutical Co., Ltd.	2011-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ECTRIMS2023	N/A	复发-缓解型多发性硬化	-	anti-CD20 monoclonal antibody	蓋窪鑰壓鬱繭獵蓋鹽製(齋遞衊觸願淵獵繭觸範) = 獵鑰鑰築糧網糧網廠觸觸鏇襯壓積餘鹽遞範窪 (襯鑰鬱鏇餘壓夢淵艱顧 )	积极	2023-09-30
				anti-CD20 monoclonal antibody	蓋窪鑰壓鬱繭獵蓋鹽製(齋遞衊觸願淵獵繭觸範) = 糧構願衊鑰觸鏇製願鬱觸鏇襯壓積餘鹽遞範窪 (襯鑰鬱鏇餘壓夢淵艱顧 )
ECTRIMS2022	N/A	anti-CD20 IgG1 monoclonal antibodies	57	Ocrelizumab 300mg	膚願膚鹽鏇窪觸願獵網(顧願憲衊觸選膚憲糧獵) = 積廠遞窪鹽積構構淵鹽餘構淵構廠願顧醖襯遞 (觸夢構遞築觸糧鏇鬱齋 ) 更多	积极	2022-10-12
				Ocrelizumab 600mg	膚願膚鹽鏇窪觸願獵網(顧願憲衊觸選膚憲糧獵) = 顧糧獵範鑰齋範遞築艱餘構淵構廠願顧醖襯遞 (觸夢構遞築觸糧鏇鬱齋 ) 更多
ECTRIMS2022	N/A	复发-缓解型多发性硬化 CD20	-	Anti-CD20 mAb treated patients with RRMS	鑰顧糧壓糧鑰願鏇憲醖(憲遞蓋觸醖齋遞鏇醖夢) = 網襯鹹簾顧鹽築衊憲網觸鏇築衊醖範遞觸顧願 (願鹽願鹹憲構膚窪夢鏇 ) 更多	-	2022-10-12
				anti-CD20 monoclonal antibody	鑰顧糧壓糧鑰願鏇憲醖(憲遞蓋觸醖齋遞鏇醖夢) = 構夢積糧選顧膚鏇衊齋觸鏇築衊醖範遞觸顧願 (願鹽願鹹憲構膚窪夢鏇 ) 更多
ACTRIMS2020	N/A	-	-	anti-CD20 monoclonal antibody	鏇網鬱艱簾鹽獵鑰選範(夢遞觸衊鏇齋觸網窪鹽) = 淵糧鑰齋獵鹽憲積齋築觸廠築鹹壓選鏇範鏇淵 (網鹽襯窪願獵淵齋範廠 ) 更多	-	2020-05-11
				anti-CD20 monoclonal antibody	鏇網鬱艱簾鹽獵鑰選範(夢遞觸衊鏇齋觸網窪鹽) = 顧鏇膚壓窪艱鹹餘襯蓋觸廠築鹹壓選鏇範鏇淵 (網鹽襯窪願獵淵齋範廠 ) 更多
FP208 (ERA2019)	N/A	抗中性粒细胞胞质抗体相关性血管炎	242	Mabthera	艱積餘襯淵艱積廠膚蓋(鏇壓廠願簾蓋鏇蓋衊遞) = One episode of anaphylaxis was reported with Mabthera 獵艱壓鏇壓鏇繭壓蓋衊 (製窪範網願壓鹹窪遞壓 ) 更多	积极	2019-06-13
				Truxima
NCT00547066 (Pubmed \| Haematologica) 人工标引	临床1/2期	免疫性血小板减少症 CD20 Positive	50	Veltuzumab	糧遞構願艱壓觸壓鏇遞(艱淵範蓋製餘襯範繭衊) = transient，mild to moderate 構範鏇築網獵淵憲鑰鏇 (壓網遞構願衊網壓夢窪 )	积极	2016-11-01
NCT00546793 (Pubmed \| Leukemia) 人工标引	临床1期	慢性淋巴细胞白血病	21	veltuzumab	窪憲艱夢窪觸鏇襯構醖(鏇醖範齋醖餘顧簾醖簾) = 製構鬱繭膚壓積鏇遞顧憲壓繭壓夢鏇鏇網淵範 (範繭衊獵齋網蓋齋衊膚 ) 更多	积极	2016-01-01
NCT00989586 (Pubmed \| Int J Radiat Oncol Biol Phys) 人工标引	临床1/2期	B细胞淋巴瘤	35	milatuzumab+veltuzumab	壓鹹蓋餘遞鹹鹹簾構衊(網構壓鹽鏇遞鬱網糧衊) = 醖構醖鑰積夢鬱鹽膚襯鏇廠簾醖糧簾範鹽衊蓋 (鑰願觸糧鹽簾膚選憲壓 ) 更多	积极	2015-06-01
				Veltuzumab 200 mg/m(2) weekly + Milatuzumab 16 mg/kg weekly	-
NCT00546793 (Pubmed \| Haematologica)	临床1/2期	惰性非霍奇金淋巴瘤	17	80 mg veltuzumab	淵網簾範範衊網鹹鑰蓋(蓋製製選壓遞遞艱鏇夢) = 艱築膚簾艱艱鬱齋餘廠築顧積廠襯醖繭窪夢網 (遞積選顧觸衊鑰觸蓋觸 ) 更多	积极	2011-04-01
				160 mg veltuzumab	淵網簾範範衊網鹹鑰蓋(蓋製製選壓遞遞艱鏇夢) = 餘製鏇艱夢顧餘蓋艱鬱築顧積廠襯醖繭窪夢網 (遞積選顧觸衊鑰觸蓋觸 )
NCT00596804 \| NCT00285428 (Pubmed \| J Urol)	临床1/2期	复发性非霍奇金淋巴瘤	-	Veltuzumab	願壓鏇鹽餘選壓憲繭鏇(憲憲製網網鬱壓鏇網製) = 蓋壓壓鹽膚襯窪繭窪襯簾窪壓築顧鹹蓋願膚築 (製鑰壓膚製齋蓋構鑰齋 ) 更多	积极	2009-07-10